Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Adv Mater ; 33(11): e2008157, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33569816

RESUMEN

Infrared optical systems are indispensable in almost all domains of society, but their performances are often restricted by bulky size, small field of view, large thermal sensitivity, high fabrication cost, etc. Here, based on the concept of catenary optics, a novel isophase streamline optimization approach is leveraged to design silicon complementary metal-oxide-semiconductor (CMOS)-compatible metasurfaces with broadband, wide-angle, and high-efficiency performances, which breaks through the glass ceiling of traditional optical technologies. By using the truly local geometric phase, a maximum diffraction efficiency approaching 100% is obtained in ultrawide spectral and angular ranges. Somewhat surprising results are shown in that wide-angle diffraction-limited imaging and laser beam steering can be realized with a record field of view up to 178°. This methodology is scalable to the entire optical band and other materials, enabling unprecedented compact infrared systems for surveillance, unmanned vehicles, medical science, etc.

2.
Phytother Res ; 35(1): 198-206, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32716080

RESUMEN

Abelmoschus manihot, also called as "Huangkui" in Chinese, is an annual flowering herb plant in the family of Malvaceae. As a traditional Chinese medicine, the ethanol extract of the flower in Abelmoschus manihot is made as Huangkui capsule and has been used for medication of the patients with kidney diseases. Its efficacy in clinical symptoms is mainly improving renal function and reducing proteinuria among the patients with chronic kidney disease, diabetic kidney disease or IgA nephropathy. The possible mechanism of Huangkui capsule treatment in kidney diseases may include reducing inflammation and anti-oxidative stress, improving immune response, protecting renal tubular epithelial cells, ameliorating podocyte apoptosis, glomerulosclerosis and mesangial proliferation, as well as inhibiting renal fibrosis. In this review, we first described chemical constituents and pharmacokinetic characteristics in ethanol extract of the flower of Abelmoschus manihot. We then summarized the clinical and epidemiological relevancies of kidney diseases particularly in the mainland of China and discussed the possible molecular mechanisms of Huangkui capsule in the treatment of kidney diseases. Finally, we prospected further research on cellular and molecular mechanisms and application of this Chinese natural medicine in kidney diseases.


Asunto(s)
Abelmoschus/química , Nefropatías Diabéticas/tratamiento farmacológico , Flores/química , Extractos Vegetales/farmacología , Insuficiencia Renal Crónica/tratamiento farmacológico , Animales , China , Medicamentos Herbarios Chinos/uso terapéutico , Fibrosis , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Medicina Tradicional China , Extractos Vegetales/química , Ensayos Clínicos Controlados Aleatorios como Asunto
3.
Drug Des Devel Ther ; 13: 2769-2776, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31496653

RESUMEN

OBJECTIVE: This study aimed to investigate the changes in inflammatory biomarkers between newly diagnosed type 2 diabetes (T2DM) patients under one-year acarbose treatments and those under metformin managements. METHODS: Seventy patients with newly diagnosed T2DM and 32 volunteers with normal glucose tolerance (normal controls, NCs) were enrolled. Seventy patients with T2DM were randomly assigned to two subgroups and treated with acarbose (n=34) or metformin (n=36) for 1 year. Blood glucose, insulin, glycosylated hemoglobin (A1C), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and inflammatory biomarker levels (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), interleukin-2 (IL-2), and ferritin) were detected at 0, 6 and 12 months. RESULTS: After adjusting for sex, the waist-to-hip ratio (WHR) and body mass index (BMI), higher fasting plasma glucose (FPG), standard meal test 1/2 hr and 2 hr glucose, TG, TC, LDL-C, IL-6, TNF-α, IL-2 and ferritin levels were observed in T2DM group than in NCs (P<0.05). After 6 months of treatment, TNF-α levels were significantly decreased in both subgroups, and IL-6 and ferritin levels were significantly decreased after 12 months (P<0.05). However, no significant differences in the IL-6, TNF-α and ferritin levels were observed between the two subgroups. Moreover, significantly higher IL-6 and TNF-α levels were detected in the T2DM group than in NCs after 12 months of treatment (P<0.05). CONCLUSION: Patients with newly diagnosed T2DM exhibited a marked chronic inflammatory state characterized by increased IL-6, TNF-α, IL-1ß, IL-2 and ferritin levels. After 1 year of treatment with acarbose or metformin, IL-6, TNF-α, IL-1ß and ferritin levels were significantly decreased compared with the baseline. The anti-inflammatory effects of acarbose and metformin were comparable and required a long-term treatment (1 year), but the characteristics were different. Further investigations are needed to determine whether this effect was independent of the hypoglycemic effects.


Asunto(s)
Acarbosa/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Inflamación/tratamiento farmacológico , Metformina/uso terapéutico , Acarbosa/administración & dosificación , Adulto , Anciano , Biomarcadores/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/diagnóstico , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Hipoglucemiantes/administración & dosificación , Inflamación/sangre , Inflamación/diagnóstico , Masculino , Metformina/administración & dosificación , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA